A recent study indicates that patients who come off blockbuster weight-loss injections like semaglutide or tirzepatide tend to recover reduced body mass at a significantly accelerated pace than those who halt traditional lifestyle plans.
Findings released in a prominent health publication points out that while overweight individuals can lose a large proportion of their body weight while undergoing treatment, the weight returns at an estimated rate of nearly a kilo each month once they quit.
"People buying such drugs must be aware of the potential of rapid rebound weight gain when the medication concludes," cautioned researcher Dr. Susan Jebb.
Such speed of recovery suggests a reversion to starting mass in about a year and a half.
Weighing Approaches
The study, which examined dozens of trials involving thousands of patients, contrasted the outcomes of GLP-1 agonists with conventional dieting.
The team note that individuals who lose weight through diet and exercise usually experience a slower creep back—approximately 0.1 kg a month—after stopping.
The Reason for the Quick Rebound
Nutrition scientists believe the mode of action of the drugs is key to understanding the amplified regain.
GLP-1 drugs copy a natural hormone called GLP-1, which moderates feelings of fullness.
"Long-term administration of the hormone levels several times higher than normal may cause the system to produce less of its own natural GLP-1, and could lessen responsiveness to its actions," explained Dr. Adam Collins, a nutrition expert.
"Withdrawal of this GLP-1 'fix' means appetite is uncontrolled, making overeating a significant risk."
A Chronic Disease?
Medical guidelines suggest the injections for individuals with weight-linked medical conditions, accompanied by recommended lifestyle changes.
Professionals argue that, given the high risk of relapse, the treatment should be considered ongoing.
This view is supported by pharmaceutical companies, who state that the findings "emphasize the chronic character of excess weight," akin to managing conditions like diabetes.
Patient Accounts
Users who have stopped the jabs report a intense resurgence of appetite.
"I experienced a switch that goes on and you become starving," recalled a patient.
The struggle is compounded if users have not established lasting lifestyle or habit changes during therapy.
Widespread Interest
Figures suggest that millions of adults in the UK have used weight-loss jabs in the last 12 months, with demand remaining high.
- Use is more common among females compared to men.
- The middle-aged demographic shows the highest usage rates.
- Many access the medications through private prescriptions rather than public health services.
Finally, experts stress that while GLP-1 drugs are effective tools for weight loss, they are not a permanent cure and maintained weight loss hinges on ongoing behavioural management.
